IPO: CinCor Pharma, Inc. Date: 07 January 2022

Symbol: CINC
Industry: Health Care
Exchange: NASDAQ
IPO Price Low: $15
IPO Price High: $17

CinCor Pharma is a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. We are conducting a Phase 2 clinical trial of CIN-107 in patients whose blood pressure is not controlled despite treatment with three antihypertensive agents and have recently initiated a separate Phase 2 clinical trial in patients with elevated aldosterone levels whose blood pressure is not controlled despite treatment with one antihypertensive agent. In addition to hypertension, we are developing CIN-107 for the treatment of primary aldosteronism and exploring its utility in ameliorating complications of chronic kidney disease.

Shares Offered: 12100000
Shares Outstanding: 36519099
Market Cap: 584305584

How to buy CinCor Pharma, Inc. stock

For more information on the CinCor Pharma, Inc. IPO please sign up using the form opposite.

IPO Exchange is dedicated to providing accurate information to help you make the best investment decisions and expand your portfolio.

Get more details on how you can invest in CinCor Pharma, Inc. by signing up below.